Hypothalamic MC4R regulates glucose homeostasis through adrenaline-mediated control of glucose reabsorption via renal GLUT2 in mice

Leticia Maria de Souza Cordeiro¹ · Arwa Elsheikh¹ · Nagavardhini Devisetty¹ · Donald A. Morgan² · Steven N. Ebert³ · Kamal Rahmouni² · Kavaljit H. Chhabra^{1,4}

Received: 11 May 2020 / Accepted: 18 August 2020 / Published online: 14 October 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract

Aims/hypothesis Melanocortin 4 receptor (MC4R) mutation is the most common cause of known monogenic obesity in humans. Unexpectedly, humans and rodents with MC4R deficiency do not develop hyperglycaemia despite chronic obesity and insulin resistance. To explain the underlying mechanisms for this phenotype, we determined the role of MC4R in glucose homeostasis in the presence and absence of obesity in mice.

Methods We used global and hypothalamus-specific MC4R-deficient mice to investigate the brain regions that contribute to glucose homeostasis via MC4R. We performed oral, intraperitoneal and intravenous glucose tolerance tests in MC4R-deficient mice that were either obese or weight-matched to their littermate controls to define the role of MC4R in glucose regulation independently of changes in body weight. To identify the integrative pathways through which MC4R regulates glucose homeostasis, we measured renal and adrenal sympathetic nerve activity. We also evaluated glucose homeostasis in adrenaline (epinephrine)-deficient mice to investigate the role of adrenaline in mediating the effects of MC4R in glucose homeostasis. We employed a graded [¹³C₆]glucose infusion procedure to quantify renal glucose reabsorption in MC4R-deficient mice. Finally, we measured the levels of renal glucose transporters in hypothalamus-specific MC4R-deficient mice and adrenaline-deficient mice using western blotting to ascertain the molecular mechanisms underlying MC4R control of glucose homeostasis.

Results We found that obese and weight-matched MC4R-deficient mice exhibited improved glucose tolerance due to elevated glucosuria, not enhanced beta cell function. Moreover, MC4R deficiency selectively in the paraventricular nucleus of the hypothalamus (PVH) is responsible for reducing the renal threshold for glucose as measured by graded [¹³C₆]glucose infusion technique. The MC4R deficiency suppressed renal sympathetic nerve activity by 50% in addition to decreasing circulating adrenaline and renal GLUT2 levels in mice, which contributed to the elevated glucosuria. We further report that adrenaline-deficient mice recapitulated the increased excretion of glucose in urine observed in the MC4R-deficient mice. Restoration of circulating adrenaline in both the MC4R- and adrenaline-deficient mice reversed their phenotype of improved glucose tolerance and elevated glucosuria, demonstrating the role of adrenaline in mediating the effects of MC4R on glucose reabsorption.

Conclusions/interpretation These findings define a previously unrecognised function of hypothalamic MC4R in glucose reabsorption mediated by adrenaline and renal GLUT2. Taken together, our findings indicate that elevated glucosuria due to low sympathetic tone explains why MC4R deficiency does not cause hyperglycaemia despite inducing obesity and insulin resistance.

Keywords Diabetes · Endocrinology · Hypothalamus · Melanocortin 4 receptor · Mouse model · Obesity

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00125-020-05289-z>) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Kavaljit H. Chhabra
Kavaljit_Chhabra@URMC.Rochester.Edu

Extended author information available on the last page of the article

Abbreviations

HBSS	Hanks' balanced salt solution
MC4R	Melanocortin 4 receptor
qPCR	Quantitative real-time PCR
<i>Pnmt</i> -KO	<i>Pnmt</i> knockout
POMC	Proopiomelanocortin

Research in context

What is already known about this subject?

- Melanocortin 4 receptor (MC4R)-deficient humans and rodents do not develop hyperglycaemia despite obesity and insulin resistance
- MC4R mutations are the most common cause of known monogenic obesity
- *Mc4r* knockout mice recapitulate the phenotype of MC4R-deficient humans

What is the key question?

- What are the molecular and physiological bases of MC4R control of glucose homeostasis?

What are the new findings?

- MC4R in the hypothalamus contributes to glucose homeostasis via regulation of renal glucose reabsorption
- Circulating adrenaline mediates the effects of hypothalamic MC4R on glucose reabsorption
- Renal glucose transporter GLUT2 mediates the effects of MC4R and adrenaline on glucosuria

How might this impact on clinical practice in the foreseeable future?

- Elevated glucosuria due to reduced renal GLUT2 may explain why individuals with MC4R deficiency do not develop hyperglycaemia despite obesity and insulin resistance. Thus, it is possible that blocking kidney-specific GLUT2 might protect against diabetes by increasing glucose excretion

PVH	Paraventricular nucleus of the hypothalamus
SGLT	Sodium–glucose cotransporter
WT	Wild-type

Introduction

The melanocortin 4 receptor (MC4R) is a primary effector of the central melanocortin system in regulating energy balance [1–5]. Mutations in the *MC4R* gene are the most common cause of known monogenic obesity in humans [1–3]. Moreover, MC4R deficiency causes insulin resistance in humans [2, 6] and rodents [1, 5, 7]. MC4R is an established therapeutic target for treating some types of obesity [8–10]. MC4R agonists have shown promising results in treating obesity in individuals that exhibit mutations in the leptin receptor or in the melanocortin signalling pathway upstream of MC4R [8–10]. In the general population, obesity and insulin resistance increase the risk of diabetes [11–15]. However, humans and rodents with MC4R deficiency either do not develop [2, 5, 16–20] or have a relatively lower risk [21] of developing hyperglycaemia despite obesity and insulin resistance. Identifying molecular mechanisms that protect MC4R-deficient individuals from developing hyperglycaemia will advance our understanding of the function of the central melanocortin system in glucose homeostasis and may facilitate the development of new therapeutics to control diabetes in the general population. Therefore, we aimed to elucidate why

MC4R deficiency does not cause hyperglycaemia despite inducing insulin resistance and obesity.

Based on our previous observations in hypothalamus-specific proopiomelanocortin (POMC)-deficient mice [22, 23], we determined the role of MC4R in glucose reabsorption to ascertain whether elevated glucosuria protects from hyperglycaemia during MC4R deficiency. We used MC4R-deficient mice that were either overweight or weight-matched compared with their wild-type (WT) littermates to investigate the role of MC4R in glucose homeostasis. In addition to global MC4R-deficient mice, we employed a Cre-Lox recombination strategy to rescue, knockout or knockdown *Mc4r* in specific nuclei of the brain to further identify the sites that control renal glucose reabsorption via the melanocortin system.

Methods

For detailed Methods, please refer to the [Electronic supplementary material](#) (ESM).

Animal care and generation of mice All mouse procedures were approved by the Institutional Animal Care and Use Committee at the University of Rochester or the University of Iowa and were performed according to the Public Health Service guidelines for the humane care and use of experimental animals. We housed mice in ventilated cages under controlled temperature (~23°C) and photoperiod (12 h light/dark cycle, lights on from 06:00 hours to 18:00 hours)

conditions and fed them Hydropac water (Lab Products, USA) and regular laboratory chow (catalogue no. 5010; LabDiet, USA). We purchased *Mc4r*^{loxTB/+} mice from the Jackson Laboratory, USA (C57BL/6J genetic background, catalogue no. 032518) and generated *Mc4r*^{loxTB/loxTB} mice and their littermate controls (representative genotypes, ESM Fig. 1). We obtained *Mc4r*^{loxP/loxP} mice [24] from D. P. Olson (University of Michigan, USA) with permission from B. B. Lowell (Harvard University, USA). We crossed these mice with *Sim1*^{Cre} (006395, the Jackson Laboratory) to knockout *Mc4r* predominantly in the paraventricular nucleus of the hypothalamus (PVH) [24] (including some other regions that express *Sim1* gene). S. Ebert provided adrenaline-deficient mice (*Pnmt* knockout [KO], phenylethanolamine *N*-methyltransferase,) that were generated by his team as described previously [25]. Experimenters were not blinded to either group assignment or to outcome assessment. See ESM [Methods](#).

Glucose/insulin tolerance tests and glucose-stimulated insulin secretion assay For glucose tolerance tests, we fasted mice for 6 h (08:00–14:00 hours) or overnight (18:00–08:00 hours) and administered glucose by oral gavage or i.p. injections. For ITTs, we fasted mice for 6 h (08:00–14:00 hours) and administered insulin by i.p. injections. Before the administration of glucose (100 mg/mouse in 300 µl 0.9% (wt/vol.) saline [154 mmol/l NaCl]; catalogue no. G8270; Sigma, USA) or insulin (15 mU/mouse; Humulin R, Eli Lilly, USA) in different cohorts of mice, we measured their baseline blood glucose levels (tail-vein blood, AlphaTRAK 2 glucometer, USA) at 0 min. Post glucose or insulin administration, we measured blood glucose levels at different times as noted in Fig. 1. We used the trapezoidal rule to calculate total AUC for further integrated analyses of the measured blood glucose levels at different times during the tests.

For glucose-stimulated insulin secretion assay in freely moving awake mice, we cannulated the carotid artery and jugular vein, and allowed the mice to recover from surgery for 3–5 days [22, 26]. On the day of the experiment, we fasted mice for 6 h (08:00–14:00 hours) and administered an i.v. bolus of 60 mg glucose then measured blood glucose and insulin levels at different times as indicated in Fig. 2a and b, respectively.

Plasma insulin and adrenaline/noradrenaline measurements We fasted mice for 6 h (08:00–14:00 hours) and collected tail blood for insulin measurements. We centrifuged the blood at 2000 g at 4°C for 20 min to separate plasma from whole blood. We measured plasma insulin levels using an ELISA (mouse insulin assay kit, catalogue no. 90080; Crystal Chem, USA). Similarly, we used ELISAs to measure plasma adrenaline (epinephrine) and noradrenaline (norepinephrine) (catalogue nos ADU39-K01 and NOU39-K01, respectively; Eagle Bioscience, USA). We did not fast mice before adrenaline or

noradrenaline assays. We euthanised mice and collected trunk blood for the assay between 14:00 hours and 15:00 hours on the day of the experiment for all the groups.

Urine glucose, sodium, protein and creatinine assays We housed mice individually in metabolic cages (Tecniplast, USA) and let them acclimate to the cages for 1 week before using them for experiments. We collected 24 h urine samples at baseline (before glucose administration) and after glucose challenge (250 mg oral, or 100–200 mg i.p. injections in 300 µl 0.9% saline). We used a glucose colorimetric test (catalogue no. 10009582; Cayman Chemical, USA) to measure urine glucose levels. Urine sodium, creatinine and protein levels were also measured by colorimetric tests according to the manufacturers' instructions (sodium, catalogue no. 211096, Abcam USA; creatinine, catalogue no. 500701, Cayman Chemical USA; protein, catalogue no. 23227, Pierce USA). The absorbance was measured using a spectrophotometer as per manufacturers' instructions (Epoch, BioTek, USA).

Restoration of *Mc4r* in different brain regions *Mc4r*^{loxTB/loxTB} mice were anaesthetised with isoflurane, placed in a stereotaxic frame (Model 1900, Kopf Instruments) and the skull was exposed for intracranial injections of AAV-Cre or AAV-GFP as described in the ESM [Methods](#).

Quantitative real-time PCR To assess expression of *Mc4r* and *Pnmt*, quantitative real-time PCR (qPCR) was performed as described previously [27]. See ESM [Methods](#) for further details.

Intracranial surgery in *Mc4r*^{loxP/loxP} mice We used the SomnoSuite system (Kent Scientific, USA) to deliver isoflurane (2–5%) to anaesthetise mice before placing them in a stereotaxic frame (Model 1900; Kopf Instruments, USA). With a continuous flow of isoflurane (2%) in mouse nose mask, the mouse skull was exposed for intracranial injections. We injected AAV-Cre-GFP or AAV-GFP (~50 nl, titre 8 × 10¹² vg/ml; University of North Carolina Vector Core, USA) bilaterally into the PVH of 7-week-old *Mc4r*^{loxP/loxP} mice (coordinates from bregma: anteroposterior, ~0.70 mm; mediolateral, ~0.22 mm; dorsoventral, ~4.80 mm) using a 33 G Hamilton syringe attached to UltraMicroPump (UMP3-1; WPI, USA). Four weeks after the administration of the viral vectors, we measured glucose tolerance and urine glucose levels in these mice.

In situ hybridisation Fluorescence in situ hybridisation was performed on 14 µm thick slices of flash frozen brains using RNAscope fluorescent multiplex reagents (ACD, USA). RNA probes for *Mc4r* or GFP (catalogue numbers 319,181-C2, 409,011; ACD) were incubated with the brain slices and signal amplification was achieved using the multiplex reagents as described previously [26, 28].

Liver glycogen levels and pyruvate tolerance test Hepatic glycogen levels were measured using colorimetric reagents from Sigma (catalogue no. MAK016, USA). For pyruvate tolerance tests, mice were fasted for 6 h and blood glucose levels were measured at baseline and at 15, 30, 60 and 120 min after the administration of sodium pyruvate (60 mg in 0.9% saline per mouse, ip; catalogue no. P5280; Sigma, USA).

Renal and adrenal sympathetic nerve activity Sympathetic nerve activity was assessed using direct multifibre recording as described in the ESM [Methods](#).

Graded [$^{13}\text{C}_6$]glucose infusion procedure Escalated doses of [$^{13}\text{C}_6$]glucose were infused into the jugular vein and blood and urine samples were collected at different times as described in ESM [Methods](#).

Isolation and culture of mouse primary renal tubular cells We isolated mouse primary renal proximal tubular epithelial cells from 8-week-old WT mice using a published protocol [29]. For the glucose transport assay, we incubated the proximal tubule cells with Hanks' balanced salt solution (HBSS) containing [$^{13}\text{C}_6$]glucose (5 mmol/l) in the presence or absence of adrenaline/noradrenaline (10 nmol/l in HBSS). The cells were grown in cell culture inserts (catalogue no. MCRP24H48; Millipore, USA) that are used for studying small molecule transport. On the day of the experiment, the labelled glucose was added to the apical (top) side of the cells in cell culture inserts (treated with 10 nmol/l adrenaline or noradrenaline in HBSS) and glucose was measured at the basolateral (bottom) side of the cells at different times as shown in Fig. 5b. [$^{13}\text{C}_6$]Glucose was measured by LC-MS assay using Shodex (USA) HILICpak VG-50 2D column by the URM Mass Spectrometry Resource Laboratory.

Restoration of adrenaline in MC4R^{PVH}- or adrenaline-deficient mice To restore the plasma adrenaline levels in mice lacking MC4R in the PVH (MC4R^{PVH}-deficient mice), we injected adrenaline (5 μg in 300 μl 0.9% saline, per mouse, i.p.), or 0.9% saline in the control group, 1 h prior to either glucose tolerance tests or placing the mice in metabolic cages for 24 h urine collections. For adrenaline-deficient mice, we infused adrenaline (1 $\mu\text{g}/\text{day}$) or 0.9% saline using Alzet 2002 osmotic pumps as described previously [27].

Western blotting We performed western blotting to measure renal GLUT1, GLUT2, sodium–glucose cotransporter (SGLT)1, SGLT2 and Na^+/K^+ -ATPase as per our published protocol [22]. For full details, see ESM [Methods](#).

Statistical analyses All data are presented as mean $\pm$ SEM. Two-tailed Student's unpaired *t* test was used to compare

results between two independent groups. Comparisons between two independent groups involving one dependent variable with repeated measures were made by repeated measures two-way ANOVA followed by a Bonferroni post hoc multiple comparison test. All analyses were performed using Prism 8.0 (GraphPad, USA) and a *p* value <0.05 was considered significant.

Results

MC4R-deficient mice have improved glucose tolerance despite obesity and insulin resistance We used *Mc4r*^{loxTB/loxTB} mice, in which MC4R deficiency can be reversed by Cre recombinase that removes the loxP-flanked transcriptional blocking sequences and rescues *Mc4r* gene expression [3]. As shown previously [1, 3], MC4R-deficient mice exhibit obesity due to hyperphagia and reduced energy expenditure. We administered equal amounts of glucose to different groups of mice, regardless of changes in their body weights, for glucose tolerance tests. We found that the MC4R-deficient mice had normal fasting blood glucose levels coupled with improved glucose tolerance despite obesity and insulin resistance (male: Fig. 1; female: ESM Fig. 2). Moreover, IPGTTs also showed that MC4R-deficient mice have improved glucose tolerance compared with their littermate controls (Male: AUC, 2184 ± 158 vs 2852 ± 72 , female: AUC, 2421 ± 190 vs 2946 ± 128 mmol/l $\times$ min, MC4R-deficient vs WT, respectively, *p* <0.05).

MC4R-deficient mice exhibit elevated glucosuria but no enhancement in beta cell function We performed a glucose-stimulated insulin secretion assay to determine if an increase in insulin secretion to compensate for the insulin resistance can explain the improved glucose tolerance in MC4R-deficient mice. Supporting the results obtained from the OGTT and IPGTT, the IVGTT also demonstrated improved glucose tolerance in MC4R-deficient mice (Fig. 2a). WT mice showed a significantly higher increase in glucose-stimulated insulin secretion compared with baseline (time 0, Fig. 2b). In contrast, there was no such increase in insulin secretion in response to glucose challenge in MC4R-deficient mice (Fig. 2b), which already have elevated baseline plasma insulin levels due to insulin resistance. These data indicate that enhanced glucose-induced insulin secretion is not the underlying cause of improved glucose tolerance in MC4R-deficient mice.

Based on our observation of elevated glucosuria in hypothalamus-specific POMC-deficient mice [22, 23], we measured urine glucose levels in MC4R-deficient mice. Indeed, the MC4R-deficient mice exhibited elevated glucosuria at baseline and after glucose administration compared with their WT

Fig. 1 Improved glucose tolerance despite insulin resistance in 6 h fasted obese male *Mc4r* null 24-week-old C57Bl/6 mice. **(a)** Body weight, **(b)** OGTT, **(c)** fasting plasma insulin levels, **(d)** ITT in obese *Mc4r* null 24-week-old C57Bl/6 mice. Bar graphs in **(b)** and **(d)** represent the corresponding AUC. Two-tailed unpaired Student's *t* test or repeated measures two-way ANOVA followed by Bonferroni's multiple comparison test were used for comparisons. ***p* < 0.01, ****p* < 0.001. Error bars are mean $\pm$ SEM. *Mc4r*^{-/-}, *Mc4r*^{loxTB/loxTB}

littermates (Fig. 2c–e). Moreover, the MC4R-deficient mice had increased 24 h urine volume and exhibited natriuresis without any changes in creatinine and total protein levels (ESM Table 1 and ESM Fig. 3). Taking into account 24 h urine volume, the MC4R-deficient mice exhibited an increase of total glucose excretion of different magnitude and intensity,

depending on the route and amount of glucose administration, compared with their control littermates, as shown in ESM Table 1.

MC4R in the PVH controls glucose reabsorption *Mc4r* is expressed in the PVH, medial amygdala and lateral

Fig. 2 Elevated glucosuria but no enhancement in beta cell function post glucose administration in obese male *Mc4r* null 24-week-old C57Bl/6 mice. **(a)** Blood glucose levels during the IVGTT (mice were fasted for 6 h before the test); *n* = 7 WT and *n* = 6 *Mc4r*^{-/-}, **(b)** plasma insulin levels during IVGTT; *n* = 7, **(c)** 24 h urine glucose concentration at baseline, **(d)** 24 h urine glucose concentration after administering 250 mg glucose by

oral gavage, **(e)** 24 h urine glucose concentration after administering 200 mg glucose by i.p. injection. Two-tailed unpaired Student's *t* test or repeated measures two-way ANOVA followed by Bonferroni's multiple comparison test were used for comparisons. ***p* < 0.01, ****p* < 0.001 vs WT; †*p* < 0.01 vs 0 min, WT. Error bars are mean $\pm$ SEM. *Mc4r*^{-/-}, *Mc4r*^{loxTB/loxTB}

Fig. 3 Improved glucose tolerance and elevated glucosuria in male 18- to 24-week-old hypothalamus-specific *Mc4r* knockout mice. **(a)** Body weight, **(b)** OGTT (mice were fasted for 6 h before the test), **(c)** 24 h urine glucose concentration in *Mc4r^{loxP/loxP};Sim1^{Cre}* mice. **(d)** Representative images of fluorescence in situ hybridisation showing reduced *Mc4r* in the PVH; $n = 5$, four sections per mouse and four areas of interest per section were analysed. Scale bar, 100 μm. **(e)** Body weight,

(f) OGTT, **(g)** urine [¹³C₆]glucose levels in *Mc4r^{loxP/loxP}*+AAV-Cre mice during the graded glucose infusion procedure; $n = 5$. Bar graphs in **(b)** and **(f)** represent the corresponding AUC. Two-tailed unpaired Student's *t* test or repeated measures two-way ANOVA followed by Bonferroni's multiple comparison test were used for comparisons. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Error bars are mean $\pm$ SEM. 3 V, third ventricle

hypothalamus, in addition to hindbrain regions, such as the nucleus tractus solitarius (NTS) and rostral ventrolateral medulla (RVLM) [30]. To identify the areas that mediate the effects of MC4R on kidney glucose reabsorption and glucose homeostasis, we restored *Mc4r* in different brain regions in reversible *Mc4r^{loxTB/loxTB}* using the Cre-Lox strategy [3]. We injected AAV-Cre or AAV-GFP into the above-mentioned *Mc4r* expressing areas in different cohorts of *Mc4r^{loxTB/loxTB}* mice. We confirmed the accuracy of the injections by measuring *Mc4r* expression in each of the regions using qPCR at the end of the study (ESM Fig. 4a). Mice that did not show significant restoration of *Mc4r* expression after the injections were excluded from the experiments or data analyses. We found

that restoration of *Mc4r* in the PVH reversed the phenotype of improved glucose tolerance and elevated glucosuria observed in otherwise global MC4R-deficient mice (ESM Fig. 4b, c). These data indicated that PVH-specific MC4R (*Mc4r^{PVH}*) is sufficient to maintain glucose homeostasis through renal glucose reabsorption.

To investigate whether MC4R in the PVH is necessary for glucose reabsorption, we used two mouse models: *Mc4r^{loxP/loxP};Sim1^{Cre}* and *Mc4r^{loxP/loxP}* with AAV-Cre administration selectively into the PVH in adult mice.

Obese *Mc4r^{loxP/loxP};Sim1^{Cre}* mice had improved glucose tolerance and elevated glucosuria like that observed in global MC4R-deficient mice (Fig. 3a–c), demonstrating the role of

Fig. 4 Reduced renal sympathetic nerve activity and adrenal *Pnmt* expression in male 8- to 16-week-old *Mc4r^{loxP/loxP};Sim1^{Cre}* mice vs *Mc4r^{loxP/loxP}* mice. **(a)** Plasma adrenaline, **(b)** plasma noradrenaline. **(c)** Representative traces of blood pressure, renal sympathetic nerve activity (RSNA) and adrenal sympathetic nerve activity (ADSNA). **(d)** RSNA, **(e)** ADSNA and **(f)** adrenal *Pnmt* expression in male 8- to 16-week-old *Mc4r^{loxP/loxP};Sim1^{Cre}* mice vs *Mc4r^{loxP/loxP}* mice. Two-tailed unpaired Student's *t* test was used for comparisons. **p* < 0.05, ***p* < 0.01, ****p* < 0.001. Error bars are mean ± SEM. RVI, resetting voltage integration

hypothalamic MC4R in glucose regulation. Results from weight-matched mice also supported this phenotype (ESM Fig. 5). It is important to note that the weight-matched *Mc4r^{loxP/loxP};Sim1^{Cre}* mice did not exhibit elevated glucosuria at baseline (ESM Fig. 5d) because they were not fed ad libitum and, therefore, their blood glucose levels at baseline remained below the renal threshold for glucose excretion. However, the mice did show elevated glucosuria (ESM Fig. 5e) after we administered 250 mg glucose by oral gavage, further validating the role of MC4R in glucose reabsorption.

To account for any developmental or compensatory changes, or a possible non-specific knockout of *Mc4r* outside the PVH, which may have impacted the results obtained from *Mc4r^{loxP/loxP};Sim1^{Cre}* mice, we also determined glucose homeostasis in adult *Mc4r^{loxP/loxP}* mice that were made

MC4R^{PVH} deficient by administration of AAV-Cre selectively in the PVH, as described previously [3, 26]. In line with the findings in *Mc4r^{loxP/loxP};Sim1^{Cre}* mice, the obese MC4R^{PVH}-deficient mice (Fig. 3d) also showed improved glucose tolerance and elevated glucosuria (Fig. 3e–g). The number of cells expressing *Mc4r* in the PVH was reduced by 70% without any difference in the total number of cells (DAPI staining) after AAV-Cre administration compared with the mice that received AAV-GFP/control vector (AAV-Cre: 217 ± 21 vs AAV-GFP: 721 ± 51, *n* = 5, four sections per mouse and four areas of interest per section were analysed, number of cells expressing *Mc4r*, *p* < 0.01). Accuracy of intra-PVH injections was confirmed after the study by observing the expression of GFP in the PVH. Data from only those mice that had GFP confined to the PVH were used for analyses (ESM Fig. 6a).

Fig. 5 Adrenaline increases glucose transport in the mouse primary renal tubular epithelial (RPTE) cells and reverses improved glucose tolerance and elevated glucosuria in hypothalamus-specific MC4R-deficient mice. **(a)** Schematic of the experiment setup and cell culture inserts. **(b)** $[^{13}\text{C}_6]\text{Glucose}$ levels after treatment with adrenaline or noradrenaline in the RPTE cells; $n = 5$ **(c)** OGTT, **(d)** 24 h urine glucose concentration at baseline, **(e)** 24 h urine glucose concentration after administering 250 mg

glucose by oral gavage in 18- to 24-week-old $Mc4r^{\text{loxP/loxP}}$ +AAV-Cre mice whose plasma adrenaline levels are restored. Two-tailed unpaired Student's *t* test or repeated measures two-way ANOVA followed by Bonferroni's multiple comparison test were used for comparisons. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ for adrenaline vs noradrenaline and HBSS groups in **(b)** and for adrenaline group vs saline group in **(c–e)**. Adr, adrenaline; Nor-Adr, noradrenaline; Sal, saline

We did not observe any differences in the hepatic glycogen levels and gluconeogenesis between WT and the MC4R-deficient ($Mc4r^{\text{loxTB/loxTB}}$) mice (ESM Fig. 6b, c). Moreover, renal *Mc4r* expression was negligible compared with that in the hypothalamus in WT mice ($Mc4r$: $0.6 \pm 0.2\%$ vs $100 \pm 12\%$, kidney vs hypothalamus, respectively, $p < 0.001$). Altogether, these data demonstrate that MC4R in the PVH regulates glucose homeostasis via renal glucose reabsorption.

MC4R deficiency reduces renal sympathetic nerve activity and circulating adrenaline levels To determine the integrative pathways that link the hypothalamic MC4R and kidney glucose reabsorption, we measured circulating adrenaline levels, renal and adrenal sympathetic nerve activities in $Mc4r^{\text{loxP/loxP}};Sim1^{\text{Cre}}$ mice. We observed that $Mc4r^{\text{loxP/loxP}};Sim1^{\text{Cre}}$ mice had reduced plasma adrenaline and noradrenaline levels (Fig. 4a,b). Moreover, the MC4R deficiency in *Sim1* neurons suppressed the renal sympathetic nerve activity by 50% compared with their control littermates without affecting blood pressure (Fig. 4c,d).

Unexpectedly, the $Mc4r^{\text{loxP/loxP}};Sim1^{\text{Cre}}$ mice had increased adrenal sympathetic nerve activity (Fig. 4e) despite the reduced circulating adrenaline levels. The increased sympathetic tone was probably a compensatory response to the reduced *Pnmt* expression (Fig. 4f) and consequent decrease in adrenaline synthesis. Taken together, the results

indicate the essential role of the hypothalamic MC4R in regulating renal and adrenal sympathetic nerve activity that likely affect circulating adrenaline and noradrenaline levels.

Adrenaline increases glucose transport in the mouse primary renal tubular cells We determined the direct effects of adrenaline and noradrenaline (both 10 nmol/l in HBSS) on glucose transport in the mouse primary renal tubular cells isolated from 8-week-old WT mice using $[^{13}\text{C}_6]\text{glucose}$ (5 mmol/l) to identify the hormone that integrates the effects of the hypothalamic MC4R on glucose reabsorption. We found that glucose transport was increased across the cell culture inserts (Fig. 5a), representing glucose reabsorption, in the adrenaline- but not the noradrenaline-treated group compared with the control group (Fig. 5b). These data indicate the direct role of adrenaline in glucose reabsorption.

Restoration of adrenaline reverses the improved glucose tolerance and elevated glucosuria in MC4R^{PVH}-deficient mice Because we observed that adrenaline increased glucose transport in primary renal tubular cells, we hypothesised that adrenaline would reverse elevated glucosuria in MC4R^{PVH}-deficient mice. To test this hypothesis, we injected adrenaline (5 μg in 300 μl 0.9% saline per mouse) or saline into MC4R^{PVH}-deficient mice ($Mc4r^{\text{loxP/loxP}}$ +AAV-Cre mice) to restore their plasma adrenaline levels and measured glucose

Fig. 6 Blood and urine glucose levels in male 6- to 9-week-old mice before (a–g) and after (h–k) restoration of their plasma adrenaline levels. (a) Plasma adrenaline, (b) plasma noradrenaline, (c) OGTT, (d) 24 h urine glucose concentration at baseline, (e) 24 h urine glucose concentration after administering 250 mg glucose by oral gavage in adrenaline-deficient mice, (f) ITT, (g) plasma insulin levels in adrenaline-deficient mice, (h) plasma adrenaline (to validate its restoration), (i) OGTT, (j) 24 h urine glucose concentration at

baseline and (k) 24 h urine glucose concentration after administering 100 mg glucose by i.p. injection, following restoration of plasma adrenaline in otherwise adrenaline-deficient mice. Bar graphs in (c), (f) and (i) represent the corresponding AUC. Two-tailed unpaired Student's *t* test or repeated measures two-way ANOVA followed by Bonferroni's multiple comparison test were used for comparisons. **p* < 0.05, ***p* < 0.01, ****p* < 0.001. Error bars are mean ± SEM. Adr, adrenaline; Sal, saline

tolerance in addition to urine glucose levels. Circulating adrenaline in MC4R^{PVH}-deficient mice was reduced (6461 ± 1179 vs $18,227 \pm 3918$ pmol/l, *p* < 0.05) compared with their littermate controls. The restoration of adrenaline reversed the improved

glucose tolerance and elevated glucosuria in the MC4R^{PVH}-deficient mice (Fig. 5c–e). These data demonstrate the role of adrenaline in integrating the effects of the hypothalamic MC4R in glucose homeostasis via the reabsorption of glucose.

Adrenaline-deficient mice recapitulate the phenotype of elevated glucosuria that was observed in MC4R-deficient mice We found that *Pnmt*-KO (adrenaline-deficient) mice (Fig. 6a,b) had improved glucose tolerance and elevated glucosuria compared with their WT littermates (Fig. 6c–e). There was no change in 24 h urine volume between the adrenaline-deficient mice and the controls (1006 ± 277 vs 1058 ± 107 μ l, *Pnmt*-KO vs WT, respectively). Moreover, there was no difference in the hepatic glycogen levels between WT and adrenaline-deficient mice (ESM Fig. 6d). Adrenaline-deficient mice had hyperinsulinaemia, but not reduced insulin sensitivity as measured by ITT (Fig. 6f,g).

We implanted osmotic minipumps (1 μ g/day adrenaline or saline, s.c.) to restore plasma adrenaline (Fig. 6h) in otherwise adrenaline-deficient mice to validate the essential role of adrenaline in glucose homeostasis via glucose reabsorption. We evaluated glucose tolerance on the 4th day and measured urine glucose levels on the 12th day of the infusion. Adrenaline infusion reversed the improved glucose tolerance and the elevated glucosuria observed in the adrenaline-deficient mice (Fig. 6i–k) without affecting liver glycogen levels (ESM Fig. 6f). Together, these data point to the direct role of adrenaline in systemic glucose homeostasis via renal glucose reabsorption independently of changes in insulin sensitivity.

Decreased renal GLUT2 is responsible for elevated glucosuria in MC4R- and adrenaline-deficient mice Renal GLUT2 was decreased by 20–25% in both MC4R^{PVH}- and adrenaline-deficient mice compared with their littermate controls (Fig. 7a,b). In contrast, the levels of SGLT2, SGLT1, and GLUT1 were not different between the groups (ESM Fig. 7). Adrenaline treatment restored renal GLUT2 levels in MC4R^{PVH}-deficient and adrenaline-deficient mice (Fig. 7c,d). These results indicate the role of renal GLUT2 in mediating the effects of hypothalamic MC4R and adrenaline on glucose reabsorption.

To explain how the reduced renal GLUT2 increases glucosuria in MC4R^{PVH}- and adrenaline-deficient mice, we measured the levels and activity of Na⁺/K⁺-ATPase in the plasma membrane fractions of the kidneys. The Na⁺ gradient maintained by Na⁺/K⁺-ATPase in the renal proximal tubular cells facilitates glucose reabsorption [31]. However, a decrease in GLUT2 causes accumulation of glucose in the proximal tubular cells (as depicted in the Graphical Abstract), which in turn is known to inhibit Na⁺/K⁺-ATPase [32, 33]. Consistent with these findings, both the MC4R^{PVH}- and adrenaline-deficient mice had reduced levels and activity of Na⁺/K⁺-ATPase (Fig. 7e–h). The reduced Na⁺/K⁺-ATPase activity also probably accounts for natriuresis in MC4R^{PVH}-deficient mice. Taken together, these results indicate that MC4R^{PVH}- and adrenaline-deficient mice exhibit elevated glucosuria because of reduced renal GLUT2 and probably due to consequent decrease in renal Na⁺/K⁺-ATPase activity.

Discussion

Statement of principal findings We have identified elevated glucosuria as a mechanism by which MC4R-deficient mice remain protected from hyperglycaemia despite obesity and insulin resistance. We report an essential role of the hypothalamic MC4R in renal glucose reabsorption through the effects of adrenaline on renal GLUT2.

Strengths and weaknesses of the study A major strength of this study is that we have used both global and hypothalamus-specific MC4R-deficient obese or lean mice (male and female) to precisely define the brain regions that contribute to glucose homeostasis via MC4R. Moreover, MC4R deficiency was induced either since birth or in adult mice to account for the confounding effects of developmental or compensatory changes on glucose homeostasis. We employed a state-of-the-art graded [¹³C₆]glucose infusion procedure and primary mouse kidney cells to further validate the effects of MC4R/adrenaline on glucose reabsorption.

A major weakness of this study is that we did not determine whether acute renal sympathetic nerve stimulation is enough to increase glucose reabsorption via renal GLUT2, which is beyond the scope of this study. We observed a 20–25% reduction in renal GLUT2 levels in MC4R-deficient mice. Although this moderate reduction in GLUT2 levels is sufficient to cause elevated glucosuria and maintain normal blood glucose levels in MC4R-deficient mice, we speculate that kidney-specific *Glut2* knockout mice will exhibit significantly higher glucosuria than that observed in MC4R-deficient mice, and further establish the function of renal GLUT2 in regulating systemic glucose homeostasis.

Strengths and weaknesses in relation to other studies Both weight-matched and obese MC4R-deficient mice showed hyperinsulinaemia and reduced insulin sensitivity to decrease blood glucose levels compared with their WT littermates. These data support previous observations that MC4R directly regulates plasma insulin levels and insulin sensitivity independently of obesity [7, 16]. Few previous studies had reported hyperglycaemia in *Mc4r* null mice fed ad libitum [1, 34, 35]. *Mc4r* null mice exhibit hyperphagia, which confounds blood glucose levels without fasting because the mice may consume food just before blood sample collection. Moreover, in most of the previous studies that evaluated glucose tolerance tests in *Mc4r* null mice [36–38], the amount of glucose was administered based on the mouse body weight; thereby disproportionately increasing the amount of glucose delivered in obese *Mc4r* null mice relative to their lean controls. Such a practice may misdiagnose obese mice as having impaired glucose tolerance. In clinical research or practice, a fixed amount of glucose (75 g) is administered orally to measure glucose tolerance in humans, regardless of their body weight [39].

Fig. 7 Decreased renal GLUT2 and Na⁺/K⁺-ATPase levels/activity in hypothalamus-specific MC4R- and adrenaline-deficient mice. **(a, b)** Decreased renal cortical GLUT2 levels in hypothalamus-specific MC4R-deficient (*Mc4r*^{PVH}) **(a)** and adrenaline-deficient (*Pnmt*-KO) **(b)** mice. **(c, d)** Increased renal cortical GLUT2 levels after treatment with adrenaline in hypothalamus-specific MC4R-deficient **(c)** and *Pnmt*-KO **(d)** mice. **(e, f)** Decreased renal Na⁺/K⁺-ATPase levels in hypothalamus-specific MC4R-deficient **(e)** and *Pnmt*-KO **(f)** mice. **(g, h)** Decreased

renal Na⁺/K⁺-ATPase activity in hypothalamus-specific MC4R-deficient **(g)** and *Pnmt*-KO **(h)** mice. Proteins of interest and internal control were probed on the same membrane as described in the Methods. Two-tailed unpaired Student's *t* test was used for comparisons. **p* < 0.05, ***p* < 0.01, ****p* < 0.001. Error bars are mean ± SEM. Adr, adrenaline; Sal, saline; *Mc4r*^{PVH}, *Mc4r*^{loxP/loxP} with AAV-Cre; Ctrl, *Mc4r*^{loxP/loxP} with AAV-GFP

Similarly, a fixed dose of glucose is also recommended for glucose tolerance tests in animal studies to avoid confounding effects of obesity on glucose clearance [40–42]. The bedding material of the mouse cages is another factor that could have confounded blood glucose levels in the reports that demonstrate either unchanged [20] or impaired [4] glucose tolerance in *Mc4r* null mice. It is critical to use aspen wood chip bedding

(we use this material) in mouse cages for experiments that involve fasting because mice eat standard bedding materials such as corncob, as reported by the Jackson Laboratory [43] and supported empirically by our previous reports [22, 23].

Human MC4R deficiency decreases sympathetic tone as measured by adrenaline and noradrenaline levels in urine [44]. Consistent with our previous report [26], MC4R^{PVH}-

deficient mice exhibited reduced circulating adrenaline and noradrenaline levels. We further show in the current study that MC4R deficiency selectively in the *Sim1* neurons decreases renal sympathetic nerve activity. The low sympathetic tone also protects MC4R-deficient mice and humans from hypertension [17, 44–46]. Moreover, MC4R-deficient mice have normal Bowman's space, glomerular area, mesangial matrix, albumin excretion, renal TGF- β and collagen expression [17], indicating that the elevated excretion of glucose observed in our present study is not the outcome of any known renal injury in these mice.

GLUT2 mutations cause glucosuria in mice [47, 48] and humans [49, 50]. Renal GLUT2 is increased in rodent models of diabetes [51, 52], causing enhanced glucose reabsorption and worsening hyperglycaemia. GLUT2 is also present in the liver and may be affected by adrenaline [53]. However, it is known that hepatocytes from *Glut2* knockout mice do not exhibit any changes in glucose transport because of redundant glucose regulating pathways in the liver [54]. Moreover, liver-specific GLUT2-deficient mice [55] have normal glucose tolerance until the loss of beta cells, after which the mice start to show impaired glucose tolerance. In contrast, we report that reduced renal GLUT2 improved glucose tolerance in MC4R^{PVH}- and adrenaline-deficient mice by elevating glucosuria, demonstrating the function of kidney-specific GLUT2 in systemic glucose homeostasis.

Unanswered questions and future research The decrease in circulating adrenaline levels in the MC4R-deficient mice was likely caused by the combination of reduced renal sympathetic nerve activity and reduced adrenal *Pnmt* expression. Renal sympathetic nerve activity [56] and enzymes [57, 58] in the kidneys other than phenylethanolamine *N*-methyltransferase (PNMT) are reported to contribute to circulating or urine adrenaline levels. However, the mechanisms underlying the hypothalamic MC4R regulation of *Pnmt* expression and subsequently, secretion or synthesis of adrenaline are as yet unclear. Moreover, it is unknown whether MC4R signalling regulates renal Na⁺/K⁺-ATPase directly or secondary to renal GLUT2. Future studies are necessary to answer these questions.

Conclusion In summary, this study demonstrates that MC4R selectively in the PVH contributes to glucose homeostasis by regulating glucose reabsorption via circulating adrenaline and renal GLUT2. These findings indicate that MC4R deficiency does not cause hyperglycaemia, even in the face of insulin resistance and obesity, because of elevated glucosuria mediated by low sympathetic tone.

Acknowledgements We thank D. P. Olson (University of Michigan, Ann Arbor, MI, USA), B. B. Lowell (Harvard University, Cambridge, MA,

USA) for providing *Mc4r*^{loxP/loxP} mice; V. Vallon (University of California, San Diego, CA, USA), L. Harrison-Bernard (LSUHSC, New Orleans, LA, USA) for discussion and critical comments on the research design of, and results obtained from, this study; G. Pryhuber, C. Poole and S. Mack (URMC Pediatric Histology Service, Rochester, NY, USA) for their help with cryostat and brain sections; K. Welle (University of Rochester Mass Spectrometry Resource Laboratory, Rochester, NY, USA) for help with the [¹³C₆]glucose assay; V. K. Thomas and J. Zhang (URMC Center for Advanced Light Microscopy and Nanoscopy, Rochester, NY, USA) for help with microscopy. Some of the findings of this study were reported in abstract form at ENDO 2020, Endocrine Society Meeting.

Data availability Data related to this manuscript are available on request from the authors.

Funding This study was supported by funding from an Endocrine Fellows Foundation grant to AE. NIDDK/NIH DK113115 and DK122190 grants, in addition to Pilot Research Award and Startup funds from the Department of Medicine, URM, to KHC. NIH/NHLBI HL084207, Department of Veterans Affairs BX004249, funding from the University of Iowa Fraternal Order of Eagles Diabetes Research Center and the Iowa Neuroscience Institute to KR. NIH instrument grant S10OD025242 to University of Rochester Mass Spectrometry Resource Laboratory. The URM Pediatric Histology Service is supported by the Department of Pediatrics at the University of Rochester and NHLBI/NIH HL122700 and HL148861 grants to G. H. Deutsch, T. J. Mariani, and G. S. Pryhuber.

Authors' relationships and activities The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement LMC, AE and ND designed and performed experiments, analysed results, wrote and edited the manuscript. DAM and KR performed, and analysed the results obtained from, the sympathetic nerve activity experiments in addition to editing the manuscript. SNE generated the *Pnmt*-KO mouse model, helped with interpretation and analyses of the data from *Pnmt*-KO mice, and edited the manuscript. KHC conceived the study, designed and performed experiments, analysed results, wrote and edited the manuscript. All authors read and approved the final manuscript. KHC is the guarantor of this work.

References

1. Huszar D, Lynch CA, Fairchild-Huntress V et al (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* 88(1):131–141. [https://doi.org/10.1016/S0092-8674\(00\)81865-6](https://doi.org/10.1016/S0092-8674(00)81865-6)
2. Farooqi IS, Yeo GS, Keogh JM et al (2000) Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. *J Clin Invest* 106(2):271–279. <https://doi.org/10.1172/JCI9397>
3. Balthasar N, Dalgaard LT, Lee CE et al (2005) Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell* 123(3):493–505. <https://doi.org/10.1016/j.cell.2005.08.035>
4. Berglund ED, Liu T, Kong X et al (2014) Melanocortin 4 receptors in autonomic neurons regulate thermogenesis and glycemia. *Nat Neurosci* 17(7):911–913. <https://doi.org/10.1038/nn.3737>
5. Tan HY, Steyn FJ, Huang L, Cowley M, Veldhuis JD, Chen C (2016) Hyperphagia in male melanocortin 4 receptor deficient mice

- promotes growth independently of growth hormone. *J Physiol* 594(24):7309–7326. <https://doi.org/10.1113/jp272770>
6. Ramachandrapa S, Farooqi IS (2011) Genetic approaches to understanding human obesity. *J Clin Invest* 121(6):2080–2086. <https://doi.org/10.1172/JCI46044>
 7. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L (2001) Central melanocortin receptors regulate insulin action. *J Clin Invest* 108(7):1079–1085. <https://doi.org/10.1172/jci12954>
 8. Kuhnlen P, Clement K, Wiegand S et al (2016) Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. *N Engl J Med* 375(3):240–246. <https://doi.org/10.1056/NEJMoa1512693>
 9. Collet TH, Dubern B, Mokrosinski J et al (2017) Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. *Mol Metab* 6(10):1321–1329. <https://doi.org/10.1016/j.molmet.2017.06.015>
 10. Clement K, Biebermann H, Farooqi IS et al (2018) MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. *Nat Med* 24(5):551–555. <https://doi.org/10.1038/s41591-018-0015-9>
 11. Kahn BB, Flier JS (2000) Obesity and insulin resistance. *J Clin Invest* 106(4):473–481. <https://doi.org/10.1172/jci10842>
 12. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 444(7121):840–846. <https://doi.org/10.1038/nature05482>
 13. Ganz ML, Wintfeld N, Li Q, Alas V, Langer J, Hammer M (2014) The association of body mass index with the risk of type 2 diabetes: a case–control study nested in an electronic health records system in the United States. *Diabetol Metab Syndr* 6(1):50. <https://doi.org/10.1186/1758-5996-6-50>
 14. Wainberg M, Mahajan A, Kundaje A et al (2019) Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: a Mendelian randomization study. *PLoS Med* 16(12):e1002982. <https://doi.org/10.1371/journal.pmed.1002982>
 15. Schnurr TM, Jakupović H, Carrasquilla GD et al (2020) Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study. *Diabetologia* 63:1324–1334. <https://doi.org/10.1007/s00125-020-05140-5>
 16. Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD (2000) The central melanocortin system can directly regulate serum insulin levels. *Endocrinology* 141(9):3072–3079. <https://doi.org/10.1210/endo.141.9.7665>
 17. do Carmo JM, Tallam LS, Roberts JV et al (2009) Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice. *Am J Physiol Regul Integr Comp Physiol* 297(3):R803–R812. <https://doi.org/10.1152/ajpregu.00187.2009>
 18. Iepsen EW, Zhang J, Thomsen HS, et al. (2018) Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. *Cell Metab* 28(1):23–32.e23. <https://doi.org/10.1016/j.cmet.2018.05.008>
 19. Stepp DW, Osakwe CC, Belin de Chantemele EJ, Mintz JD (2013) Vascular effects of deletion of melanocortin-4 receptors in rats. *Physiol Rep* 1(6):e00146. <https://doi.org/10.1002/phy2.146>
 20. Litt MJ, Okoye GD, Lark D et al (2017) Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy. *Elife* 6:e28118. <https://doi.org/10.7554/eLife.28118>
 21. Baron M, Maillet J, Huyvaert M et al (2019) Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. *Nat Med* 25(11):1733–1738. <https://doi.org/10.1038/s41591-019-0622-0>
 22. Chhabra KH, Adams JM, Fagel B et al (2016) Hypothalamic POMC deficiency improves glucose tolerance despite insulin resistance by increasing glycosuria. *Diabetes* 65(3):660–672. <https://doi.org/10.2337/db15-0804>
 23. Chhabra KH, Morgan DA, Tooke BP, Adams JM, Rahmouni K, Low MJ (2017) Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice. *Mol Metab* 6(10):1274–1285. <https://doi.org/10.1016/j.molmet.2017.07.005>
 24. Shah BP, Vong L, Olson DP et al (2014) MC4R-expressing glutamatergic neurons in the paraventricular hypothalamus regulate feeding and are synaptically connected to the parabrachial nucleus. *Proc Natl Acad Sci* 111(36):13193. <https://doi.org/10.1073/pnas.1407843111>
 25. Ebert SN, Rong Q, Boe S, Pfeifer K (2008) Catecholamine-synthesizing cells in the embryonic mouse heart. *Ann N Y Acad Sci* 1148:317–324. <https://doi.org/10.1196/annals.1410.008>
 26. Tooke BP, Yu H, Adams JM et al (2019) Hypothalamic POMC or MC4R deficiency impairs counterregulatory responses to hypoglycemia in mice. *Mol Metab* 20:194–204. <https://doi.org/10.1016/j.molmet.2018.11.004>
 27. Chhabra KH, Adams JM, Jones GL et al (2016) Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity. *Mol Metab* 5(10):869–881. <https://doi.org/10.1016/j.molmet.2016.07.012>
 28. Wang F, Flanagan J, Su N et al (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J Mol Diagn* 14(1):22–29. <https://doi.org/10.1016/j.jmoldx.2011.08.002>
 29. Ding W, Yousefi K, Shehadeh LA (2018) Isolation, characterization, and high throughput extracellular flux analysis of mouse primary renal tubular epithelial cells. *J Vis Exp* 136:57718. <https://doi.org/10.3791/57718>
 30. Liu H, Kishi T, Roseberry AG et al (2003) Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. *J Neurosci* 23(18):7143–7154. <https://doi.org/10.1523/jneurosci.23-18-07143.2003>
 31. Ghezzi C, Loo DDF, Wright EM (2018) Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. *Diabetologia* 61(10):2087–2097. <https://doi.org/10.1007/s00125-018-4656-5>
 32. Rivelli JF, Amaiden MR, Monesterolo NE et al (2012) High glucose levels induce inhibition of Na,K-ATPase via stimulation of aldose reductase, formation of microtubules and formation of an acetylated tubulin/Na,K-ATPase complex. *Int J Biochem Cell Biol* 44(8):1203–1213. <https://doi.org/10.1016/j.biocel.2012.04.011>
 33. Owada S, Larsson O, Arkhammar P et al (1999) Glucose decreases Na⁺,K⁺-ATPase activity in pancreatic beta-cells. An effect mediated via Ca²⁺-independent phospholipase A2 and protein kinase C-dependent phosphorylation of the α -subunit. *J Biol Chem* 274(4):2000–2008. <https://doi.org/10.1074/jbc.274.4.2000>
 34. Itoh M, Suganami T, Nakagawa N et al (2011) Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. *Am J Pathol* 179(5):2454–2463. <https://doi.org/10.1016/j.ajpath.2011.07.014>
 35. Ste Marie L, Miura GI, Marsh DJ, Yagaloff K, Palmiter RD (2000) A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. *Proc Natl Acad Sci U S A* 97(22):12339–12344. <https://doi.org/10.1073/pnas.220409497>
 36. Morgan DA, McDaniel LN, Yin T et al (2015) Regulation of glucose tolerance and sympathetic activity by MC4R signaling in the lateral hypothalamus. *Diabetes* 64(6):1976–1987. <https://doi.org/10.2337/db14-1257>
 37. You P, Hu H, Chen Y et al (2016) Effects of melanocortin 3 and 4 receptor deficiency on energy homeostasis in rats. *Sci Rep* 6:34938–34938. <https://doi.org/10.1038/srep34938>
 38. Mosialou I, Shikhel S, Liu J-M et al (2017) MC4R-dependent suppression of appetite by bone-derived lipocalin 2. *Nature* 543(7645):385–390. <https://doi.org/10.1038/nature21697>

39. ADA (2018) 2. Classification and Diagnosis of Diabetes: Standards of Medical care in diabetes—2018. *Diabetes Care* 41(Suppl 1): S13–S27. <https://doi.org/10.2337/dc18-S002>
40. McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH (2009) NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. *Am J Physiol Endocrinol Metab* 297(4):E849–E855. <https://doi.org/10.1152/ajpendo.90996.2008>
41. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J (2008) Evaluating the glucose tolerance test in mice. *Am J Physiol Endocrinol Metab* 295(6):E1323–E1332. <https://doi.org/10.1152/ajpendo.90617.2008>
42. Ayala JE, Samuel VT, Morton GJ et al (2010) Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. *Dis Model Mech* 3(9–10):525–534. <https://doi.org/10.1242/dmm.006239>
43. Garcia-Arocena D (2014) 7 Tips every dio mice user should know. Available from <https://www.jax.org/news-and-insights/jax-blog/2014/may/seven-tips-every-dio-mice-user-should-know>. Accessed 05 Nov 2019
44. Greenfield JR, Miller JW, Keogh JM et al (2009) Modulation of blood pressure by central melanocortinergic pathways. *N Engl J Med* 360(1):44–52. <https://doi.org/10.1056/NEJMoa0803085>
45. Tallam LS, Stec DE, Willis MA, da Silva AA, Hall JE (2005) Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. *Hypertension* 46(2):326–332. <https://doi.org/10.1161/01.HYP.0000175474.99326.bf>
46. Samuelsson A-MS, Mullier A, Maicas N et al (2016) Central role for melanocortin-4 receptors in offspring hypertension arising from maternal obesity. *Proc Natl Acad Sci U S A* 113(43):12298–12303. <https://doi.org/10.1073/pnas.1607464113>
47. Guillam M-T, Hümmeler E, Schaerer E et al (1997) Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. *Nat Genet* 17(3):327–330. <https://doi.org/10.1038/ng1197-327>
48. Thorens B, Guillam MT, Beermann F, Burcelin R, Jaquet M (2000) Transgenic reexpression of GLUT1 or GLUT2 in pancreatic beta cells rescues GLUT2-null mice from early death and restores normal glucose-stimulated insulin secretion. *J Biol Chem* 275(31):23751–23758. <https://doi.org/10.1074/jbc.M002908200>
49. Sakamoto O, Ogawa E, Ohura T et al (2000) Mutation analysis of the GLUT2 gene in patients with Fanconi–Bickel syndrome. *Pediatr Res* 48(5):586–589. <https://doi.org/10.1203/00006450-200011000-00005>
50. Grunert SC, Schwab KO, Pohl M, Sass JO, Santer R (2012) Fanconi–Bickel syndrome: GLUT2 mutations associated with a mild phenotype. *Mol Genet Metab* 105(3):433–437. <https://doi.org/10.1016/j.ymgme.2011.11.200>
51. Kamran M, Peterson RG, Dominguez JH (1997) Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. *J Am Soc Nephrol* 8(6):943–948
52. Chin E, Zama AM, Landau D et al (1997) Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. *Endocrinology* 138(3):1267–1275. <https://doi.org/10.1210/endo.138.3.5015>
53. Miura T, Kato M, Iwamoto N et al (2000) Effect of epinephrine on GLUT2 protein content in mouse liver. *Biol Pharm Bull* 23(11): 1374–1376. <https://doi.org/10.1248/bpb.23.1374>
54. Guillam MT, Burcelin R, Thorens B (1998) Normal hepatic glucose production in the absence of GLUT2 reveals an alternative pathway for glucose release from hepatocytes. *Proc Natl Acad Sci U S A* 95(21):12317–12321. <https://doi.org/10.1073/pnas.95.21.12317>
55. Seyer P, Vallois D, Poitry-Yamate C et al (2013) Hepatic glucose sensing is required to preserve β cell glucose competence. *J Clin Invest* 123(4):1662–1676. <https://doi.org/10.1172/JCI65538>
56. Zhang WH, Zhou QN, Lu YM et al (2018) Renal denervation reduced ventricular arrhythmia after myocardial infarction by inhibiting sympathetic activity and remodeling. *J Am Heart Assoc* 7(20):e009938. <https://doi.org/10.1161/jaha.118.009938>
57. Ziegler MG, Kennedy B, Elayan H (1989) Rat renal epinephrine synthesis. *J Clin Invest* 84(4):1130–1133. <https://doi.org/10.1172/JCI114276>
58. Ziegler MG, Aung M, Kennedy B (1997) Sources of human urinary epinephrine. *Kidney Int* 51(1):324–327. <https://doi.org/10.1038/ki.1997.40>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Leticia Maria de Souza Cordeiro¹ · Arwa Elsheikh¹ · Nagavardhini Devisetty¹ · Donald A. Morgan² · Steven N. Ebert³ · Kamal Rahmouni² · Kavaljit H. Chhabra^{1,4}

¹ Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

² Department of Neuroscience and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA, USA

³ Division of Metabolic and Cardiovascular Sciences, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA

⁴ Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, USA